ARCH Venture Partners

Kardigan is a patient-driven heart health firm that is revolutionizing cardiovascular drug development to produce medicines that take patients from symptom management to functional cures.

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Seaport Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for patients with significant unmet needs. The company's approach emphasizes the creation of treatments that offer oral bioavailability, which allows the medications to bypass first-pass metabolism. This method aims to reduce hepatotoxicity and other adverse side effects commonly associated with neuropsychiatric treatments. By addressing these critical issues, Seaport Therapeutics seeks to improve the quality of life for individuals living with neuropsychiatric disorders.

Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to continue their research work and discover drugs. It was founded in 2016 and is headquartered in Seattle, Washington.

Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in advancing drug discovery through its innovative microfluidic platform. This technology allows for precise control of thousands of droplets, enabling complex cell analysis and workflows without manual manipulation. By leveraging this platform, Lightcast collaborates with major pharmaceutical companies and leading academic institutions to develop new therapies and products. The company's focus is on pushing the boundaries of complex cell analysis, thereby facilitating the discovery of unique clinical approaches in the field of drug development.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Human Immunology Biosciences is a biotechnology company dedicated to developing therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company specializes in precision medicine and focuses on discovering and creating transformative therapies. Its lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has demonstrated the ability to deplete CD38+ cells, including plasma cells and natural killer cells, in clinical studies. This mechanism may enhance clinical outcomes across a range of immune-mediated diseases, offering improved treatment options for patients suffering from these conditions.

Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

ONI is a leader in super-resolution microscopy, offering innovative tools that enhance biological research. The company has developed the Nanoimager, the first benchtop super-resolution microscope, which provides unprecedented usability and precision for researchers. This device enables access to various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by academic researchers and pharmaceutical companies, with installations in prominent laboratories such as those at the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize scientific discovery by making advanced imaging technology more accessible and affordable, thereby empowering researchers to visualize and share the intricate details of life. Recognized for its innovative contributions, ONI has received accolades such as being named a Disruptor to Watch and winning Best Business Start-up at the IOP Awards. Through its commitment to advancing scientific research, ONI aims to accelerate discoveries that can lead to improved health outcomes.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Resilience is a technology-driven biomanufacturing company focused on enhancing access to complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. The firm aims to transform the production of medicine by providing a comprehensive range of customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals throughout all stages of drug development, from pre-clinical to commercial supply. Resilience is committed to creating a sustainable network of advanced manufacturing solutions that ensure rapid, safe, and scalable production of treatments, thereby enabling partners to concentrate on breakthrough discoveries that improve patient outcomes. The company's innovative approach also strengthens biopharmaceutical supply chains, preparing them for future challenges.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Epirium Bio, Inc. is a San Diego-based biopharmaceutical company focused on developing therapeutic compounds for cardiovascular diseases, metabolic syndrome, and various conditions related to mitochondrial dysfunction. Founded in 2008 and previously known as Cardero Therapeutics, Epirium Bio utilizes innovative insights into mitochondrial biology and tissue regeneration to create small molecule therapies. The company's research is aimed at enhancing muscle strength and supporting the treatment of neuromuscular and neurodegenerative disorders, including conditions such as muscular dystrophy. Through its novel approaches, Epirium Bio seeks to provide clinically significant solutions for patients suffering from these challenging diseases.

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of medicines for chronic illnesses, particularly infectious diseases, liver, and lung conditions. Founded in 2018, the company operates from Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to provide innovative biopharmaceutical solutions tailored to the needs of Chinese patients, addressing public health challenges such as hepatitis B, HIV, and multidrug-resistant infections. The company leverages technology and data to enhance the Chinese healthcare system, ensuring better access to effective treatments. With a diverse pipeline of over ten product candidates, Brii Biosciences is committed to improving health outcomes for patients suffering from both infectious and central nervous system diseases.

CStone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative immuno-oncology and molecularly targeted drugs aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2015 and headquartered in Shanghai, China, the company has established a robust product pipeline that includes several late-stage clinical candidates, such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, which targets programmed death receptor. Other notable products include ivosidenib, avapritinib, and pralsetinib, along with a variety of additional investigational drugs for solid tumors and other cancer indications. CStone engages in strategic collaborations, including a licensing agreement with Numab Therapeutics for a tri-specific antibody and a clinical partnership with Bayer HealthCare to assess the efficacy of CS1001 in combination therapies. The company aims to enhance treatment options for cancer patients both in China and globally through its dedicated research and development efforts.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that focuses on the discovery and development of innovative therapeutic products for unmet medical needs. Founded by former executives from Receptos, the company aims to leverage a strong in-licensing strategy and a team with extensive experience in immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, which targets pulmonary arterial hypertension; GB004, aimed at treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, designed for various oncology indications; and GB001, intended for moderate-to-severe eosinophilic asthma. Through these efforts, Gossamer Bio seeks to improve patient outcomes in critical therapeutic areas.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York that focuses on discovering and developing therapies targeting phosphoinositide (PI) signaling pathways. Established in 2015, the company aims to create novel small molecules that address serious medical conditions, particularly cancer and metabolic diseases. By honing in on unique enzyme targets involved in critical cellular processes such as cell division, growth, trafficking, and signaling, Petra Pharma seeks to develop innovative treatments that can enhance human health and provide new options for healthcare providers.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

SAGE Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders. The company's lead product is ZULRESSO, an intravenous formulation of brexanolone designed for treating postpartum depression. SAGE's pipeline includes several advanced candidates, such as SAGE-217, currently in Phase III trials for various depressive disorders and anxiety, and SAGE-324, which is in Phase II trials for essential tremors. Additionally, SAGE-718 is being explored for multiple conditions, including depression and Alzheimer's disease, having completed its Phase I trials. The company has established strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. to enhance the development and commercialization of its therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts, SAGE Therapeutics aims to address significant unmet needs in brain health through its scientific innovations and partnerships.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company based in Warren, New Jersey, focused on developing innovative treatments for cardiopulmonary diseases. The company's primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform designed to address various forms of pulmonary hypertension. Currently, INOpulse is undergoing multiple Phase 2 clinical trials, targeting pulmonary hypertension associated with interstitial lung disease, chronic obstructive pulmonary disease, sarcoidosis, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension related to high altitude sickness and COVID-19. In addition to INOpulse, Bellerophon is also developing a bioabsorbable cardiac matrix (BCM), an injectable device aimed at preventing cardiac remodeling and congestive heart failure following myocardial infarction. Bellerophon was established in 2009 and previously operated as Ikaria Development LLC before rebranding in 2014.

Boreal is committed to improving cancer patient care through the development of research tools and diagnostic tests based on the monitoring of tumor mutations from cell-free DNA in plasma. It also provides novel DNA enrichment and library construction solutions for high accuracy sequencing in liquid biopsy applications. The company's OnTarget platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs. Boreal Genomics was founded in 2007 and is based in Vancouver, BC, Canada.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Receptos, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the discovery and development of therapeutics for immune disorders. The company’s lead product, ozanimod, is an oral therapy currently undergoing phase III trials for relapsing multiple sclerosis and phase II trials for ulcerative colitis and Crohn's disease. Additionally, Receptos is developing RPC4046, a monoclonal antibody in phase II trials for eosinophilic esophagitis, an allergic and immune-mediated condition. The company is also engaged in research on glucagon-like peptide-1 receptor small molecule positive allosteric modulators, which are in preclinical studies for treating Type 2 diabetes. Founded in 2008, Receptos was initially known as Receptor Pharmaceuticals, Inc. and rebranded in May 2009. As of August 2015, Receptos operates as a subsidiary of Celgene Corporation.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.

Receptos, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the discovery and development of therapeutics for immune disorders. The company’s lead product, ozanimod, is an oral therapy currently undergoing phase III trials for relapsing multiple sclerosis and phase II trials for ulcerative colitis and Crohn's disease. Additionally, Receptos is developing RPC4046, a monoclonal antibody in phase II trials for eosinophilic esophagitis, an allergic and immune-mediated condition. The company is also engaged in research on glucagon-like peptide-1 receptor small molecule positive allosteric modulators, which are in preclinical studies for treating Type 2 diabetes. Founded in 2008, Receptos was initially known as Receptor Pharmaceuticals, Inc. and rebranded in May 2009. As of August 2015, Receptos operates as a subsidiary of Celgene Corporation.

Permeon Biologics aims to enhance human health by using their novel Intraphilin Technology Platform™ to enable intracellular biologics as a revolutionary new generation of therapeutic drugs.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes various NK- and T-cell immuno-oncology programs, such as FT516 for acute myeloid leukemia and B-cell lymphoma, FT596 for B-cell lymphoma and chronic lymphocytic leukemia, and FT538 for multiple myeloma. Additional programs include FT500, FT576, FT819, and FT-ONO1, targeting solid tumors and hematologic malignancies. Fate Therapeutics is also collaborating with Ono Pharmaceutical Co. Ltd. and Janssen Biotech, Inc. to advance its off-the-shelf iPSC-derived CAR T-cell therapies and other innovative treatments. Founded in 2007, the company leverages insights from leading scientists to create and modulate stem cells for therapeutic applications, aiming to restore health through advanced cellular therapies.

Bluebird Bio is a biotechnology company focused on the research, development, and commercialization of innovative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D, for cerebral adrenoleukodystrophy. In oncology, Bluebird Bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company collaborates with several partners, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to discover and commercialize disease-altering therapies. Additional collaborations with organizations such as Medigene AG and Gritstone Oncology focus on developing T cell receptor product candidates for cancer treatment. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird Bio aims to fundamentally address the genetic basis of diseases through its proprietary lentiviral vector gene addition platform. Revenue is generated from collaboration agreements, research fees, license fees, and grants.

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing immunotherapies targeting Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Founded in 2006, the company’s lead investigational drug, Motolimod, works by mobilizing the patient's immune system to fight cancer through the activation of myeloid dendritic cells, monocytes, and natural killer cells. VentiRx's product pipeline includes VTX-2337, a TLR8 agonist aimed at enhancing immune responses against solid tumors and specific cancers such as ovarian and breast cancer, as well as VTX-1463, designed to address allergies. The company is also exploring TLR8 antagonists for autoimmune diseases and compounds intended as vaccine adjuvants. VentiRx Pharmaceuticals operates as a subsidiary of Celgene Corporation and has additional operations in San Diego.

Receptos, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the discovery and development of therapeutics for immune disorders. The company’s lead product, ozanimod, is an oral therapy currently undergoing phase III trials for relapsing multiple sclerosis and phase II trials for ulcerative colitis and Crohn's disease. Additionally, Receptos is developing RPC4046, a monoclonal antibody in phase II trials for eosinophilic esophagitis, an allergic and immune-mediated condition. The company is also engaged in research on glucagon-like peptide-1 receptor small molecule positive allosteric modulators, which are in preclinical studies for treating Type 2 diabetes. Founded in 2008, Receptos was initially known as Receptor Pharmaceuticals, Inc. and rebranded in May 2009. As of August 2015, Receptos operates as a subsidiary of Celgene Corporation.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes various NK- and T-cell immuno-oncology programs, such as FT516 for acute myeloid leukemia and B-cell lymphoma, FT596 for B-cell lymphoma and chronic lymphocytic leukemia, and FT538 for multiple myeloma. Additional programs include FT500, FT576, FT819, and FT-ONO1, targeting solid tumors and hematologic malignancies. Fate Therapeutics is also collaborating with Ono Pharmaceutical Co. Ltd. and Janssen Biotech, Inc. to advance its off-the-shelf iPSC-derived CAR T-cell therapies and other innovative treatments. Founded in 2007, the company leverages insights from leading scientists to create and modulate stem cells for therapeutic applications, aiming to restore health through advanced cellular therapies.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Limerick BioPharma focuses on creating innovative pharmaceutical compounds designed to enhance the efficacy of existing and experimental drugs, while reducing harmful side effects on non-targeted organs and tissues. The company aims to improve patient quality of life by developing adjunctive therapies that work in conjunction with other medications. Additionally, Limerick BioPharma is advancing novel treatments for metabolic diseases, specifically targeting conditions like hypercholesteremia and hyperglycemia. They employ advanced methodologies to simulate blood-tissue barrier activity both in laboratory settings and in living organisms, positioning them at the forefront of research in metabolic disorders and solid organ transplantation.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Lycera is a preclinical-stage biopharmaceutical company dedicated to the development of small molecule immunomodulators aimed at treating autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company specializes in creating first-in-class drugs that utilize proprietary small molecules to modulate key targets involved in cellular bioenergetics and the Th17 pathway. Lycera's innovative approach seeks to provide effective oral therapies that minimize the adverse effects commonly associated with existing antiproliferative and immunosuppressive treatments. By focusing on the development of these novel agents, Lycera aims to improve patient outcomes in the management of immune disorders.

Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Limerick BioPharma focuses on creating innovative pharmaceutical compounds designed to enhance the efficacy of existing and experimental drugs, while reducing harmful side effects on non-targeted organs and tissues. The company aims to improve patient quality of life by developing adjunctive therapies that work in conjunction with other medications. Additionally, Limerick BioPharma is advancing novel treatments for metabolic diseases, specifically targeting conditions like hypercholesteremia and hyperglycemia. They employ advanced methodologies to simulate blood-tissue barrier activity both in laboratory settings and in living organisms, positioning them at the forefront of research in metabolic disorders and solid organ transplantation.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes various NK- and T-cell immuno-oncology programs, such as FT516 for acute myeloid leukemia and B-cell lymphoma, FT596 for B-cell lymphoma and chronic lymphocytic leukemia, and FT538 for multiple myeloma. Additional programs include FT500, FT576, FT819, and FT-ONO1, targeting solid tumors and hematologic malignancies. Fate Therapeutics is also collaborating with Ono Pharmaceutical Co. Ltd. and Janssen Biotech, Inc. to advance its off-the-shelf iPSC-derived CAR T-cell therapies and other innovative treatments. Founded in 2007, the company leverages insights from leading scientists to create and modulate stem cells for therapeutic applications, aiming to restore health through advanced cellular therapies.

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.